Pacira BioSciences Inc PCRX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PCRX is a good fit for your portfolio.
News
-
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
-
Thinking about buying stock in Healthequity, Pacira Biosciences, Interpublic Group of Companies, SIGA Technologies, or Sensus Healthcare?
-
Pacira's PCRX-201 Gets FDA RMAT Designation in Knee Osteoarthritis
-
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
-
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
-
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
-
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
-
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
Trading Information
- Previous Close Price
- $26.82
- Day Range
- $25.79–26.61
- 52-Week Range
- $25.74–48.58
- Bid/Ask
- $25.91 / $25.98
- Market Cap
- $1.21 Bil
- Volume/Avg
- 155,079 / 498,113
Key Statistics
- Price/Earnings (Normalized)
- 8.99
- Price/Sales
- 2.02
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Value
- Total Number of Employees
- 712
- Website
- https://www.pacira.com
Comparables
Valuation
|
Metric
|
PCRX
|
VSBC
|
FTRE
|
|---|---|---|---|
Price/Earnings (Normalized) | 8.99 | 3,629.76 | 66.40 |
Price/Book Value | 1.40 | 1,908.62 | 1.89 |
Price/Sales | 2.02 | 664.53 | 1.05 |
Price/Cash Flow | 6.81 | 2,904.34 | 26.96 |
Price/Earnings
PCRX
VSBC
FTRE
Financial Strength
|
Metric
|
PCRX
|
VSBC
|
FTRE
|
|---|---|---|---|
Quick Ratio | 3.94 | 4.32 | 1.52 |
Current Ratio | 5.24 | 4.33 | 1.62 |
Interest Coverage | 3.90 | — | 1.02 |
Quick Ratio
PCRX
VSBC
FTRE
Profitability
|
Metric
|
PCRX
|
VSBC
|
FTRE
|
|---|---|---|---|
Return on Assets (Normalized) | 5.46% | 42.38% | 1.15% |
Return on Equity (Normalized) | 10.58% | 65.38% | 2.40% |
Return on Invested Capital (Normalized) | 6.20% | 55.23% | 3.06% |
Return on Assets
PCRX
VSBC
FTRE
Drug Manufacturers - Specialty & Generic Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
MKKGY
| Merck KGaA ADR | Cldvlbwzw | Tkbrpwn | $71.2 Bil | |
ZTS
| Zoetis Inc Class A | Ffktnvlwh | Bvj | $68.3 Bil | |
HLN
| Haleon PLC ADR | Wgpgdmk | Vmp | $37.5 Bil | |
TEVA
| Teva Pharmaceutical Industries Ltd ADR | Vcckwpf | Nwcwm | $14.5 Bil | |
VTRS
| Viatris Inc | Hfkgpnt | Twncr | $13.4 Bil | |
RDY
| Dr Reddy's Laboratories Ltd ADR | Vzrtgnz | Xcvq | $11.9 Bil | |
CTLT
| Catalent Inc | Vdscpmk | Kxdcbkz | $10.1 Bil | |
PRGO
| Perrigo Co PLC | Wvckkbtk | Wpnk | $4.1 Bil | |
CURLF
| Curaleaf Holdings Inc | Lzvccgkwg | Lgfk | $3.6 Bil | |
PBH
| Prestige Consumer Healthcare Inc | Ghrqjyz | Rfbxdh | $3.5 Bil |